Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis

Neurology

Volumn 63, Issue 4, 2004, Pages 713-714

  Lane, Margaret ^a   McBride, John ^a   Archer, John ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE;

ADULT; ARACHNOIDITIS; ARTICLE; CASE REPORT; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; HEADACHE; HUMAN; HYDROCEPHALUS; IMMUNOCOMPETENCE; LUMBAR PUNCTURE; MALE; MENINGITIS; PRIORITY JOURNAL; STROKE; SUBARACHNOID SPACE;

EID: 4143148494     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000134677.29120.62     Document Type: Article

References (6)

1. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of cryptococcus neoformans. Clin Infect Dis 1995;21: 28-34.
2. Lan S, Chang W, Lu C, Lui C, Chang H. Cerebral infarction in chronic meningitis: a comparison of tuberculous meningitis and cryptococcal meningitis. Q J Med 2001;94:247-253.
3. Fisher D, Burrow J, Lo D, Currie B. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust N Z J Med 1993;23:678-682.
4. Mitchell D, Sorrell T, Allworth A, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20:611-616.
5. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000;31:499-508.
6. Saag M, Graybill R, Larsen R, et al. Practise guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30:710-718.